Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Biogaia stock price, quote, forecast and news

BIOG B.ST
SE0000470395
914755

Price

115.80 SEK
Today +/-
+0.14 SEK
Today %
+1.39 %
P

Biogaia stock price

SEK
%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Biogaia stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Biogaia stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Biogaia stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Biogaia's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Biogaia Stock Price History

DateBiogaia Price
9/5/2024115.80 SEK
9/4/2024114.20 SEK
9/3/2024117.00 SEK
9/2/2024120.00 SEK
8/30/2024120.70 SEK
8/29/2024118.50 SEK
8/28/2024118.00 SEK
8/27/2024125.00 SEK
8/26/2024125.10 SEK
8/23/2024127.80 SEK
8/22/2024126.50 SEK
8/21/2024124.80 SEK
8/20/2024126.00 SEK
8/19/2024128.60 SEK
8/16/2024124.30 SEK
8/15/2024124.80 SEK
8/14/2024124.90 SEK
8/13/2024125.10 SEK
8/12/2024125.70 SEK
8/9/2024127.20 SEK
8/8/2024124.70 SEK

Biogaia Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Biogaia, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Biogaia from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Biogaia’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Biogaia. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Biogaia’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Biogaia’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Biogaia’s growth potential.

Biogaia Revenue, EBIT and net profit per share

DateBiogaia RevenueBiogaia EBITBiogaia Net Income
2026e1.98 B SEK680.74 M SEK528.07 M SEK
2025e1.76 B SEK601.46 M SEK471.96 M SEK
2024e1.47 B SEK435.82 M SEK353.36 M SEK
20231.3 B SEK441.26 M SEK365.35 M SEK
20221.1 B SEK334.51 M SEK373.77 M SEK
2021785.11 M SEK242.13 M SEK196.27 M SEK
2020747.08 M SEK228.15 M SEK179.73 M SEK
2019768.35 M SEK242.51 M SEK187.35 M SEK
2018741.87 M SEK270.86 M SEK214.89 M SEK
2017615 M SEK234.65 M SEK180.56 M SEK
2016534.7 M SEK195.01 M SEK227.57 M SEK
2015483.24 M SEK171.09 M SEK121.41 M SEK

Biogaia Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B SEK)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M SEK)EBIT (M SEK)EBIT MARGIN (%)NET INCOME (M SEK)NET INCOME GROWTH (%)DIV. (SEK)DIV. GROWTH (%)SHARES (M)DOCUMENTS
2015201620172018201920202021202220232024e2025e2026e
0.480.530.620.740.770.750.791.11.31.471.761.98
-10.5615.1720.493.64-2.735.0940.5117.5013.2720.1012.54
69.5772.4775.2874.9073.3173.0974.1472.6273.30---
336387463555563546582801950000
171195234270242228242334441435601680
35.4036.5238.0536.4431.5130.5230.8330.2834.0329.6334.0934.27
121227180214187179196373365353471528
-87.60-20.7018.89-12.62-4.289.5090.31-2.14-3.2933.4312.10
------------
------------
17.3186.6886.6886.6886.6889.24100.96100.98100.98000
------------
Details

Keystats

ⓘ

Revenue and Growth

The Biogaia Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Biogaia is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B SEK)RECEIVABLES (M SEK)OTHER REC. (M SEK)INVENTORIES (M SEK)OTHER CURRENT LIAB. (M SEK)CURRENT ASSETS (B SEK)TANGIBLE ASSETS (M SEK)LONG-T. INVEST. (M SEK)LONG-T. REC. (M SEK)INTANGIBLE ASSETS (M SEK)GOODWILL (M SEK)OTHER NON-CURRENT ASSETS (M SEK)NON-CURRENT ASSETS (M SEK)TOTAL ASSETS (B SEK)LIABILITIESCOMMON STOCK (M SEK)ADDITIONAL PAID-IN CAPITAL (B SEK)RETAINED EARNINGS (M SEK)OTHER EQUITY (B SEK)UNREAL. GAINS/LOSSES (M SEK)EQUITY (B SEK)LIABILITIES (M SEK)PROVISIONS (M SEK)OTHER SHORT-TERM LIAB. (M SEK)SHORT-TERM DEBTS (M SEK)LONG-TERM DEBT PORTION (M SEK)SHORT-TERM REC. (M SEK)LONG-T. LIAB. (M SEK)DEFERRED TAXES (M SEK)OTHER LIAB. (M SEK)LONG-T. LIABILITIES (M SEK)DEBT (M SEK)TOTAL CAPITAL (B SEK)
201520162017201820192020202120222023
                 
0.230.240.310.290.221.471.481.491.54
74.9692.2196.83142.01129.76101.66128.15131.05106.23
14.736.358.4212.8126.5541.5420.3818.427.65
43.5540.4832.6144.2168.4572.28102.74142.84181.2
4.933.225.625.598.866.2216.1316.8215.16
0.370.390.450.490.451.691.751.81.87
83.9382.43102.47105.94149.04162.77153.64157.73213.33
7.9410.789.970.040.040.0422.2725.8428.06
0.020000.040.040.0419.080
16.230045.8552.5650.3248.0946.0846.23
0005.35.35.3149.23171.52165.17
010.439.348.436.525.282.7615.335.96
108.12103.64121.78165.56213.5223.74376.02435.56458.76
0.470.490.580.660.671.912.132.232.33
                 
17.3417.3417.3417.3417.3420.220.220.220.2
0.020.020.040.040.021.151.151.151.15
356.68377.77402.91443.98468.71576.56703.16798.43856.77
000000002.03
000000000
0.40.420.460.50.511.751.881.974.06
23.6416.9520.8934.0128.4948.0542.3132.0549.31
31.8425.3840.8957.3553.9148.7256.477.9586.36
21.5231.1349.6753.8234.8330.0919.3443.951.27
000000000
00007.578.28.911.18.8
76.9973.47111.45145.17124.8135.06126.95164.99195.74
000017.2520.710.400
0.350.330.786.6810.3411.3114.2412.5515.18
00005.63-0.0499.0964.0191.93
0.350.330.786.6833.2331.98123.7376.56107.11
77.3573.8112.22151.85158.03167.04250.69241.55302.85
0.470.490.580.660.671.912.132.214.36
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Biogaia provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Biogaia's financial health and stability.

Assets

Biogaia's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Biogaia must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Biogaia after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Biogaia's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M SEK)DEPRECIATION (M SEK)DEFERRED TAXES (M SEK)CHANGES IN WORKING CAPITAL (M SEK)NON-CASH ITEM (M SEK)PAID INTEREST (M SEK)PAID TAXES (M SEK)NET CASH FLOW FROM OPERATING ACTIVITIES (M SEK)CAPITAL EXPENDITURES (M SEK)CASH FLOW FROM INVESTING ACTIVITIES (M SEK)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M SEK)INTEREST INCOME AND EXPENSES (M SEK)NET DEBT CHANGE (M SEK)NET CHANGE IN EQUITY (B SEK)CASH FLOW FROM FINANCING ACTIVITIES (B SEK)CASH FLOW FROM OTHER FINANCING ACTIVITIES (SEK)TOTAL DIVIDENDS PAID (M SEK)NET CHANGE IN CASH FLOW (B SEK)FREE CASH FLOW (M SEK)SHARE-BASED COMPENSATION (M SEK)
201520162017201820192020202120222023
152194232277242228253361443
67671520272325
000000000
-42-49-19-102-113-23-59-57-40
1-3203-30-9-1
000000000
504349527272555480
117147222183147221221318425
-27-5-26-13-39-16-6-17-48
-31-9-26-47-39-16-126-18-50
-4-40-3300-1200-2
000000000
0000-4-7-14-9-10
0.0200001.13000
-0.07-0.12-0.13-0.16-0.181.05-0.08-0.31-0.31
---2.00-2.00-3.00-2.00-2.00-2.00-4.00
-86-124-130-156-173-65-68-301-292
0.020.020.06-0.02-0.071.250.0200.06
89.57142.32195.99169.67108.83205.18215.5301.03377.25
000000000

Biogaia stock margins

The Biogaia margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Biogaia. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Biogaia.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Biogaia's sales revenue. A higher gross margin percentage indicates that the Biogaia retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Biogaia's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Biogaia's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Biogaia's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Biogaia. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Biogaia's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Biogaia Margin History

Biogaia Gross marginBiogaia Profit marginBiogaia EBIT marginBiogaia Profit margin
2026e73.29 %34.31 %26.62 %
2025e73.29 %34.12 %26.77 %
2024e73.29 %29.67 %24.05 %
202373.29 %34.03 %28.18 %
202272.64 %30.3 %33.86 %
202174.25 %30.84 %25 %
202073.21 %30.54 %24.06 %
201973.4 %31.56 %24.38 %
201874.93 %36.51 %28.97 %
201775.34 %38.15 %29.36 %
201672.53 %36.47 %42.56 %
201569.65 %35.4 %25.12 %

Biogaia Stock Sales Revenue, EBIT, Earnings per Share

The Biogaia earnings per share therefore indicates how much revenue Biogaia has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Biogaia earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Biogaia's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Biogaia’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Biogaia's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Biogaia Revenue, EBIT and net profit per share

DateBiogaia Sales per ShareBiogaia EBIT per shareBiogaia Earnings per Share
2026e20.36 SEK0 SEK5.42 SEK
2025e18.09 SEK0 SEK4.84 SEK
2024e15.07 SEK0 SEK3.63 SEK
202312.84 SEK4.37 SEK3.62 SEK
202210.93 SEK3.31 SEK3.7 SEK
20217.78 SEK2.4 SEK1.94 SEK
20208.37 SEK2.56 SEK2.01 SEK
20198.86 SEK2.8 SEK2.16 SEK
20188.56 SEK3.12 SEK2.48 SEK
20177.1 SEK2.71 SEK2.08 SEK
20166.17 SEK2.25 SEK2.63 SEK
201527.92 SEK9.88 SEK7.01 SEK

Biogaia business model

Biogaia AB is a Swedish company specialized in the development of probiotic supplements and medical products. The company was founded in 1990 and is headquartered in Stockholm, Sweden. Biogaia is one of the most popular companies on Eulerpool.com.

Biogaia SWOT Analysis

Strengths

Biogaia AB possesses several notable strengths:

  • Strong brand reputation in the probiotics industry
  • Extensive product portfolio catering to different target markets
  • High-quality and scientifically proven products
  • Effective marketing and distribution strategies
  • Strong research and development capabilities

Weaknesses

Despite its strengths, Biogaia AB also faces certain weaknesses:

  • Dependence on a limited number of key customers
  • Limited geographical presence, primarily focused on Europe
  • Relatively high product prices compared to competitors
  • Potential vulnerability to regulatory changes in the industry

Opportunities

There are several opportunities that Biogaia AB can capitalize on:

  • Increasing global demand for probiotic products
  • Expansion into new markets, such as Asia and North America
  • Development of innovative products for specific health conditions
  • Partnerships and collaborations with healthcare providers and practitioners
  • Advancements in technology for product development and manufacturing

Threats

Biogaia AB faces certain threats that need to be managed effectively:

  • Intense competition from existing probiotic product manufacturers
  • Emergence of new market entrants with competitive offerings
  • Changing consumer preferences and trends
  • Influence of negative publicity or product-related controversies
  • Potential disruptions in the supply chain

Biogaia Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Biogaia historical P/E ratio, EBIT, and P/S ratio.

Biogaia shares outstanding

The number of shares was Biogaia in 2023 — This indicates how many shares 100.982 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Biogaia earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Biogaia's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Biogaia’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Biogaia's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Biogaia Stock splits

In Biogaia's history, there have been no stock splits.

Biogaia dividend history and estimates

In 2023, Biogaia paid a dividend amounting to 1.45 SEK. Dividend means that Biogaia distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Biogaia provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Biogaia’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Biogaia's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Biogaia Dividend History

DateBiogaia Dividend
2026e1.57 SEK
2025e1.59 SEK
2024e1.6 SEK
20231.45 SEK
20220.73 SEK
20210.68 SEK
20203.75 SEK
20191.19 SEK
20180.94 SEK
20170.87 SEK
20160.61 SEK
20150.31 SEK

Biogaia dividend payout ratio

In 2023, Biogaia had a payout ratio of 80.3%. The payout ratio indicates the percentage of the company's profits that Biogaia distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Biogaia represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Biogaia could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Biogaia's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Biogaia Payout Ratio History

DateBiogaia Payout ratio
2026e57.87 %
2025e48.3 %
2024e45 %
202380.3 %
202219.61 %
202135.08 %
2020186.2 %
201955.06 %
201837.84 %
201741.67 %
201623.13 %
20154.39 %
Unfortunately, there are currently no price targets and forecasts available for Biogaia.

Biogaia latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20240.96 SEK1.1 SEK (14.64 %)2024 Q2
3/31/20240.97 SEK1.21 SEK (24.79 %)2024 Q1
12/31/20230.6 SEK0.67 SEK (12.44 %)2023 Q4
9/30/20230.79 SEK1.01 SEK (28.21 %)2023 Q3
6/30/20230.75 SEK0.8 SEK (6.33 %)2023 Q2
3/31/20230.89 SEK1.15 SEK (29.39 %)2023 Q1
12/31/20220.62 SEK1.38 SEK (123.99 %)2022 Q4
9/30/20220.48 SEK0.79 SEK (62.95 %)2022 Q3
6/30/20220.46 SEK0.78 SEK (67.89 %)2022 Q2
3/31/20220.64 SEK0.76 SEK (17.87 %)2022 Q1
1
2
3
4
5
...
6

Eulerpool ESG Scorecard© for the Biogaia stock

Eulerpool World ESG Rating (EESG©)

77/ 100

🌱 Environment

84

👫 Social

90

🏛️ Governance

58

Environment

Scope 1 - Direct Emissions
93.5
Scope 2 - Indirect emissions from purchased energy
21
Scope 3 - Indirect emissions within the value chain
7,455
Total CO₂ emissions
114.5
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
✅
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees59
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Biogaia list of shareholders

%
Name
Stocks
Change
Date
7.95 % Fjärde AP-Fonden7,750,182012/31/2023
4.42 % Premier Asset Management Ltd4,306,888-735,16512/31/2023
3.23 % TIN Fonder3,144,17502/28/2023
3.08 % Cargill, Inc.3,000,000012/31/2023
2.44 % Tredje AP Fonden2,380,915343,19912/31/2023
2.24 % Juno Investment Partners2,187,295010/31/2023
11.46 % EQT Partners AB11,164,630012/31/2023
1.99 % Handelsbanken Kapitalförvaltning AB1,939,411-723,85012/31/2023
1.91 % AMF Tjänstepension AB1,862,368-533,61712/31/2023
1.80 % Dangoor (David)1,750,0001,750,00012/31/2022
1
2
3
4
5
...
10

Biogaia Executives and Management Board

Ms. Isabelle Ducellier51
Biogaia Chief Executive Officer (since 2018)
Compensation 5.25 M SEK
Mr. Alexander Kotsinas56
Biogaia Chief Financial Officer, Executive Vice President
Compensation 2.98 M SEK
Ms. Marika Isberg50
Biogaia Vice President, General Counsel
Compensation 2.04 M SEK
Mr. Peter Rothschild73
Biogaia Chairman of the Board
Compensation 1.31 M SEK
Mr. David Dangoor74
Biogaia Independent Vice Chairman of the Board
Compensation 575,000 SEK
1
2
3
4

Most common questions regarding Biogaia

What values and corporate philosophy does Biogaia represent?

Biogaia AB is a renowned company in the field of microbiome research and development. With a strong focus on innovation, Biogaia AB stands for excellence, integrity, and sustainability. The company's core values include maintaining high-quality standards, fostering scientific collaboration, and promoting a healthy microbiome for individuals worldwide. Biogaia AB's corporate philosophy is centered around providing evidence-based probiotics to improve health and well-being. By combining cutting-edge research, stringent quality control measures, and a commitment to sustainability, Biogaia AB has established itself as a leader in the probiotics industry.

In which countries and regions is Biogaia primarily present?

Biogaia AB is primarily present in various countries and regions worldwide. Some of the key locations where Biogaia AB operates include Sweden, its home country, as well as other Nordic countries such as Norway, Denmark, Finland, and Iceland. Additionally, Biogaia AB has a significant presence in several European markets, including Germany, France, Italy, Spain, and the United Kingdom. The company has also expanded its reach to other parts of the world, including the United States, Canada, Australia, and several countries in Asia such as China, Japan, South Korea, and India.

What significant milestones has the company Biogaia achieved?

Some significant milestones achieved by Biogaia AB include the development of innovative probiotic products, successful commercialization of these products in over 100 countries worldwide, and establishment of partnerships with various healthcare organizations. Biogaia AB has also received regulatory approvals for its probiotic solutions, paving the way for widespread use and adoption. The company has consistently demonstrated strong financial performance, exceeding market expectations and driving sustained growth. With a strong focus on research and development, Biogaia AB continues to expand its product portfolio and explore new applications for its probiotic technology, further strengthening its position in the global market.

What is the history and background of the company Biogaia?

Biogaia AB is a Swedish healthcare company that specializes in developing and selling probiotic products. Established in 1990, the company has a lengthy history of expertise in the field. Biogaia AB focuses on research, innovation, and producing high-quality probiotic solutions for individuals of all ages. With a global presence, the company is committed to improving health and well-being worldwide through its range of products. Biogaia AB's dedication to scientific advancements and its mission to provide effective and safe probiotic solutions has solidified its reputation as a leading player in the healthcare industry.

Who are the main competitors of Biogaia in the market?

The main competitors of Biogaia AB in the market include Nestlé, Procter & Gamble, Chr. Hansen Holding A/S, and Yakult Honsha Co., Ltd.

In which industries is Biogaia primarily active?

Biogaia AB is primarily active in the pharmaceutical and healthcare industries.

What is the business model of Biogaia?

The business model of Biogaia AB focuses on developing, producing, and selling probiotic products. Biogaia specializes in probiotics, which are live bacteria and yeasts that are beneficial for health. The company offers various probiotic solutions targeting different areas such as gut health, oral health, and infant health. Biogaia's products are available in the form of drops, tablets, or chewable tablets, making them convenient for consumers. The company's business model centers around research and development to continuously innovate and improve their probiotic offerings. Biogaia AB aims to provide high-quality probiotic products to enhance overall well-being.

What is the P/E ratio of Biogaia 2024?

The Biogaia P/E ratio is 33.09.

What is the P/S ratio of Biogaia 2024?

The Biogaia P/S ratio is 7.96.

What is the AlleAktien quality score of Biogaia?

The AlleAktien quality score for Biogaia is 6/10.

What is the revenue of Biogaia 2024?

The expected Biogaia revenue is 1.47 B SEK.

How high is the profit of Biogaia 2024?

The expected Biogaia profit is 353.36 M SEK.

What is the business model of Biogaia

Biogaia AB is a Swedish company specializing in the development, production, and marketing of probiotic products. The company was founded in 1990 and is headquartered in Stockholm. Biogaia operates in over 100 countries worldwide and employs over 200 employees. The company's business model is based on three main divisions: Human Health, Health Products for Animals, and Partner Products. The Human Health division is the largest division of the company and includes all products intended for human consumption. The range includes various probiotic dietary supplements, beverages, and foods, all aimed at improving the gut microbiome and promoting overall well-being. An example of a product from this division is BioGaia Protectis Drops, a probiotic dietary supplement for babies and toddlers. The product contains the probiotic strain Lactobacillus reuteri Protectis and is recommended for strengthening immune defense and preventing gastrointestinal complaints. Health products for animals include products for pets such as dogs and cats. The range includes probiotic supplements as well as care and health products. An example of a product from this division is BioGaia ProTectis Drops for dogs, which contributes to supporting the immune system and gastrointestinal functions. In the field of partner products, Biogaia collaborates with other companies to offer probiotic products in combination with their own products. An example of this is the partnership with Nestlé Health Science to develop products for the immune system and gut for adults and children. Biogaia's business model is based on the research and development of probiotic products. The company has worked closely with various universities and research institutions to develop new products and gain scientific insights into the effects of probiotics. Biogaia has filed over 200 patents for different probiotic strains, making it a leader in the industry. In addition to research and development, Biogaia also has a strong presence in the marketing and distribution of its products. The company utilizes the latest technologies and marketing strategies to sell its products worldwide. It collaborates closely with retailers, pharmacies, and other distribution partners to bring its products to the market. Overall, Biogaia's business model is focused on the development and marketing of probiotic products. The company has a strong presence in various industries tailored to the needs of customers, especially in the health and well-being sector. Biogaia's continuous research and development enable it to offer innovative products that can contribute to improving the quality of life for people and animals.

What is the Biogaia dividend?

Biogaia pays a dividend of 0.73 SEK distributed over payouts per year.

How often does Biogaia pay dividends?

The dividend cannot currently be calculated for Biogaia or the company does not pay out a dividend.

What is the Biogaia ISIN?

The ISIN of Biogaia is SE0000470395.

What is the Biogaia WKN?

The WKN of Biogaia is 914755.

What is the Biogaia ticker?

The ticker of Biogaia is BIOG B.ST.

How much dividend does Biogaia pay?

Over the past 12 months, Biogaia paid a dividend of 1.45 SEK . This corresponds to a dividend yield of about 1.25 %. For the coming 12 months, Biogaia is expected to pay a dividend of 1.59 SEK.

What is the dividend yield of Biogaia?

The current dividend yield of Biogaia is 1.25 %.

When does Biogaia pay dividends?

Biogaia pays a quarterly dividend. This is distributed in the months of June, June, June, June.

How secure is the dividend of Biogaia?

Biogaia paid dividends every year for the past 12 years.

What is the dividend of Biogaia?

For the upcoming 12 months, dividends amounting to 1.59 SEK are expected. This corresponds to a dividend yield of 1.37 %.

In which sector is Biogaia located?

Biogaia is assigned to the 'Health' sector.

Wann musste ich die Aktien von Biogaia kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Biogaia from 5/15/2024 amounting to 1.9 SEK, you needed to have the stock in your portfolio before the ex-date on 5/8/2024.

When did Biogaia pay the last dividend?

The last dividend was paid out on 5/15/2024.

What was the dividend of Biogaia in the year 2023?

In the year 2023, Biogaia distributed 0.726 SEK as dividends.

In which currency does Biogaia pay out the dividend?

The dividends of Biogaia are distributed in SEK.

All fundamentals about Biogaia

Our stock analysis for Biogaia Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biogaia Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.